default author photo

Patrick PJ Phillips

University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis

SCHOLARLY PAPERS

8

DOWNLOADS

959

TOTAL CITATIONS

4

Scholarly Papers (8)

1.

Evaluation of the Xpert MTB Host Response Assay for the Triage of Patients with Presumed Pulmonary Tuberculosis: A Multi-Site Prospective Diagnostic Accuracy Study

Number of pages: 20 Posted: 18 Jul 2023
Heidelberg University Hospital - Division of Infectious Disease and Tropical Medicine and German Centre for Infection Research, Hanoi Lung Hospital, Stellenbosch University - DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Christian Medical College - Department of Pulmonary Medicine, World Alliance for Lung and Intensive Care Medicine in Uganda (WALIMU), De La Salle Medical Health Sciences Institute, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Christian Medical College - Department of Pulmonary Medicine, Hanoi Medical University - Vietnam National Tuberculosis Programme, Stellenbosch University - DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, De La Salle Medical Health Sciences Institute, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Mulago National Referral Hospital - Division of Pulmonology and Heidelberg University Hospital - Division of Infectious Disease and Tropical Medicine and German Centre for Infection Research
Downloads 197 (386,064)
Citation 1

Abstract:

Loading...

Xpert, host response, diagnostics, tuberculosis, triage test

2.

Bedaquiline, Delamanid, Linezolid and Clofazimine for the Treatment of Rifampicin- and Fluoroquinolone-Resistant Tuberculosis (endTB-Q): A Phase 3, Open-Label, Multicentre, Randomised, Controlled, Stratified, Non-Inferiority Trial

Number of pages: 34 Posted: 06 Apr 2025
IRCSS Sacro Cuore Hospital, - Department of Infectious – Tropical Diseases and Microbiology, Interactive Research and Development Global, Singapore, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Epicentre (Paris), Interactive Research and Development (IRD), Karachi, Pakistan, Interactive Research and Development (IRD), Karachi, Pakistan, Interactive Research and Development (IRD), Karachi, Pakistan, National Scientific Center of Phthisiopulmonology, University of Tübingen - Mycobacteriology Unit, Epicentre (Paris), National Scientific Center of Phthisiopulmonology, Médecins Sans Frontières (London), University of Montpellier - Translational Research in HIV and Infectious Diseases (TransVIHMI), Médecins Sans Frontières, Mumbai, India, Médecins Sans Frontières, Geneva, Switzerland, City Center of Phthisiopulmonology, Institute of Tropical Medicine - Mycobacteriology Unit, Hanoi Medical University - Vietnam National Lung Hospital, Médecins Sans Frontières, Geneva, Switzerland, Research Center Borstel, Partners In Health Lesotho, Médecins Sans Frontières, Harvard University - Department of Global Health and Social Medicine, University of Cape Town (UCT) - Division of Clinical Pharmacology, Socios En Salud Sucursal Peru, Institute of Tropical Medicine - Mycobacteriology Unit, The Indus Hospital and Health Network, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Hanoi Lung Hospital, Hanoi Medical University - Vietnam National Tuberculosis Programme, Partners In Health Lesotho, University College London - MRC Clinical Trials Unit, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Hanoi Lung Hospital, Pham Ngoc Thach Hospital, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Socios En Salud Sucursal Peru, University of Tübingen - Mycobacteriology Unit, The Indus Hospital and Health Network, Hospital Nacional Sergio E. Bernales, Harvard University - Division of Global Health Equity, Partners In Health Lesotho, Hospital Nacional Hipólito Unanue, Lima, Harvard University - Division of Global Health Equity, Médecins sans Frontières (Paris), Harvard University - Department of Global Health and Social Medicine and Independent
Downloads 189 (401,336)

Abstract:

Loading...

MDR-TB, pre-XDR-TB, multidrug-resistant tuberculosis, pre-extesively drug-resistant tuberculosis, BDLC, personalized medicine, precision medicine, clinical trial, extensive tuberculosis disease, limited tuberculosis disease

3.

A Prospective, Randomised, Open Label Phase 2b Dose-Finding ​Trial of Delpazolid in Combination with Bedaquiline, Delamanid and Moxifloxacin for Pulmonary Tuberculosis: DECODE

Number of pages: 16 Posted: 10 Dec 2024
National Institute for Medical Research (NIMR), Radboud University Nijmegen - Radboud University Medical Center, National Institute for Medical Research (NIMR), Kibong’oto Infectious Diseases Hospital, Ifakara Health Institute, Ludwig Maximilian University of Munich (LMU), Aurum Institute, University of the Witwatersrand, Aurum Institute, National Institute for Medical Research (NIMR), Kibong’oto Infectious Diseases Hospital, Ifakara Health Institute, Ludwig Maximilian University of Munich (LMU), Ifakara Health Institute, Kibong’oto Infectious Diseases Hospital, Aurum Institute, University of St Andrews, Radboud University Nijmegen - Department of Lung Disease, Radboud University Nijmegen - Radboud University Medical Center, Radboud University Nijmegen - Radboud Institute for Health Sciences, University College London, University College London, Radboud University Nijmegen - Department of Lung Disease, LigaChem Biosciences Inc, LigaChem Biosciences Inc, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Ludwig Maximilian University of Munich (LMU) - Division of Infectious Diseases and Tropical Medicine, Radboud University Nijmegen - Radboud Institute for Health Sciences, Ludwig Maximilian University of Munich (LMU) - Division of Infectious Diseases and Tropical Medicine and Independent
Downloads 131 (554,631)

Abstract:

Loading...

Pulmonary tuberculosis, oxazolidinones, phase 2b, randomised clinical trial

4.

A Handheld 6-Lead Device for QT Interval Monitoring During Drug-Resistant Tuberculosis Treatment

Number of pages: 38 Posted: 04 Oct 2023
University of California, San Francisco (UCSF) - Division of Pulmonary and Critical Care Medicine, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), D-Prime LLC, Clario, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis and University of the Witwatersrand - Faculty of Health Sciences
Downloads 123 (588,531)

Abstract:

Loading...

Drug-resistant tuberculosis, QT interval, handheld ECG, mobile health, validation

5.

BTZ-043 Shows Good Safety and Strong Bactericidal Activity in a Combined Phase1b/2a Study in Tuberculosis Patients

Number of pages: 21 Posted: 16 Oct 2023
Ludwig Maximilian University of Munich (LMU), TASK, Ludwig Maximilian University of Munich (LMU), Ludwig Maximilian University of Munich (LMU), Ludwig Maximilian University of Munich (LMU), Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI), Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI), University of Cape Town Lung Institute, University of Cape Town Lung Institute, Ludwig Maximilian University of Munich (LMU), University College London, University of Cologne, University College London, Radboud University Nijmegen, Radboud University Nijmegen - Department of Lung Disease, Radboud University Nijmegen - Department of Lung Disease, Radboud University Nijmegen - Radboud Institute for Health Sciences, Radboud University Nijmegen - Radboud Institute for Health Sciences, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, TASK and German University of Administrative Sciences Speyer
Downloads 108 (649,907)
Citation 3

Abstract:

Loading...

Tuberculosis, btz-043, benzothiazinones, randomised trial, early bactericidal activity

6.

Comparison of Three Optimized Delivery Strategies for Completion of Isoniazid-Rifapentine (3HP) for Tuberculosis Prevention Among People Living with HIV: A Randomized Trial

Number of pages: 29 Posted: 18 Apr 2023
Makerere University - Department of Medicine, University of California, San Francisco (UCSF) - Division of Pulmonary and Critical Care Medicine, Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Infectious Diseases Research Collaboration (Uganda), Makerere University - Department of Epidemiology and Biostatistics, University of California, San Francisco (UCSF) - UCSF Center for TB, University of California, San Francisco (UCSF) - The Better Lab, University of California, San Francisco (UCSF) - The Better Lab, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Denver Health and Hospital Authority, Infectious Diseases Research Collaboration (Uganda), University of California, San Francisco (UCSF) - Center for Vulnerable Populations, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Makerere University - Child Health and Development Center, University of California, San Francisco (UCSF) - Division of Pulmonary and Critical Care Medicine, Makerere University - Department of Epidemiology and Biostatistics, Uganda Tuberculosis Implementation Research Consortium, Johns Hopkins University - Department of Epidemiology and University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis
Downloads 92 (730,864)

Abstract:

Loading...

HIV/AIDS, tuberculosis, rifapentine-isoniazid, 3HP, effectiveness-implementation hybrid, person-centered care, tuberculosis preventive therapy, shared decision making

7.

Increased Bactericidal Activity But Dose-Limiting Tolerability at 50 mg/kg Rifampicin

Number of pages: 41 Posted: 31 Mar 2020
Radboud University Nijmegen - Department of Lung Disease, TASK Applied Science, University of Cape Town (UCT) - University of Cape Town Lung Institute, TASK Applied Science, Radboud University Nijmegen - Department of Pharmacy, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, St. Andrews University, Ludwig Maximilian University of Munich (LMU) - Division of Infectious Diseases and Tropical Medicine, Ludwig Maximilian University of Munich (LMU) - CIHLMU Center for International Health, University of Cape Town Lung Institute, TASK Applied Science, Radboud University Nijmegen - Department of Pharmacy, Radboud University Nijmegen - Department of Lung Disease and Independent
Downloads 64 (924,743)

Abstract:

Loading...

maximum tolerable dose; high-dose rifampicin; pharmacokinetics; early bactericidal activity; dose optimization; exposure-response

8.

Final 18-month Outcomes of a Trial of Four-Month Rifapentine Regimens With or Without Moxifloxacin for Tuberculosis

Number of pages: 18 Posted: 20 Feb 2026
University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Centers for Disease Control and Prevention (U.S., Medical University of South Carolina, Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Vanderbilt University - Medical Center, University of California, San Francisco (UCSF) - Department of Bioengineering and Therapeutic Sciences, Case Western Reserve University, Bio Analytical Research Corporation South Africa (BARC SA), National Lung Hospital, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Centers for Disease Control and Prevention (U.S., Johns Hopkins University, University of Nebraska Medical Center and University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis
Downloads 55 (1,010,164)

Abstract:

Loading...

tuberculosis, non-inferiority, rifapentine, moxifloxacin